Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes
- PMID: 9132006
- DOI: 10.1021/bi962724m
Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes
Abstract
Substoichiometric binding of taxol to tubulin in microtubules potently suppresses microtubule dynamics, which appears to be the most sensitive antiproliferative mechanism of taxol. To determine whether the beta-tubulin isotype composition of a microtubule can modulate sensitivity to taxol, we measured the effects of substoichiometric ratios of taxol bound to tubulin in microtubules on the dynamics of microtubules composed of purified alphabeta(II)-, alphabeta(III)-, or alphabeta(IV)-tubulin isotypes and compared the results with the effects of taxol on microtubules assembled from unfractionated tubulin. Substoichiometric ratios of bound taxol in microtubules assembled from purified beta-tubulin isotypes or unfractionated tubulin potently suppressed the shortening rates and the lengths shortened per shortening event. Correlation of the suppression of the shortening rate with the stoichiometry of bound taxol revealed that microtubules composed of purified alphabeta(II)-, alphabeta(III)-, and alphabeta(IV)-tubulin were, respectively, 1.6-, 7.4-, and 7.2-fold less sensitive to the effects of bound taxol than microtubules assembled from unfractionated tubulin. These results indicate that taxol differentially modulates microtubule dynamics depending upon the beta-tubulin isotype composition. The results are consistent with recent studies correlating taxol resistance in tumor cells with increased levels of beta(III0- and beta(IV)-tubulin expression and suggest that altered cellular expression of beta-tubulin isotypes can be an important mechanism by which tumor cells develop resistance to taxol.
Similar articles
-
Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism.Cancer Res. 1998 Mar 15;58(6):1177-84. Cancer Res. 1998. PMID: 9515803
-
The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.Mol Pharmacol. 1997 Oct;52(4):613-22. Mol Pharmacol. 1997. PMID: 9380024
-
Characterization of nuclear betaII-tubulin in tumor cells: a possible novel target for taxol.Cell Motil Cytoskeleton. 2002 Sep;53(1):39-52. doi: 10.1002/cm.10060. Cell Motil Cytoskeleton. 2002. PMID: 12211114
-
Taxol®: The First Microtubule Stabilizing Agent.Int J Mol Sci. 2017 Aug 9;18(8):1733. doi: 10.3390/ijms18081733. Int J Mol Sci. 2017. PMID: 28792473 Free PMC article. Review.
-
Mechanisms of Taxol resistance related to microtubules.Oncogene. 2003 Oct 20;22(47):7280-95. doi: 10.1038/sj.onc.1206934. Oncogene. 2003. PMID: 14576838 Free PMC article. Review.
Cited by
-
The Caenorhabditis elegans microtubule-severing complex MEI-1/MEI-2 katanin interacts differently with two superficially redundant beta-tubulin isotypes.Mol Biol Cell. 2004 Jan;15(1):142-50. doi: 10.1091/mbc.e03-06-0418. Epub 2003 Oct 17. Mol Biol Cell. 2004. PMID: 14565976 Free PMC article.
-
Differential partitioning of Galphai1 with the cellular microtubules: a possible mechanism of development of Taxol resistance in human ovarian carcinoma cells.J Mol Signal. 2006 Nov 10;1:3. doi: 10.1186/1750-2187-1-3. J Mol Signal. 2006. PMID: 17224078 Free PMC article.
-
Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Oncotarget. 2017 Jun 6;8(23):37923-37934. doi: 10.18632/oncotarget.13544. Oncotarget. 2017. PMID: 27888622 Free PMC article. Review.
-
Nuclear βII-Tubulin and its Possible Utility in Cancer Diagnosis, Prognosis and Treatment.Front Cell Dev Biol. 2022 May 30;10:870088. doi: 10.3389/fcell.2022.870088. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35706904 Free PMC article.
-
Aptamers as both drugs and drug-carriers.Biomed Res Int. 2014;2014:697923. doi: 10.1155/2014/697923. Epub 2014 Sep 11. Biomed Res Int. 2014. PMID: 25295268 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources